• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Roivant Sciences Ltd. (Amendment)

    2/14/24 4:46:41 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email
    SC 13G/A 1 eps11181.htm
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    Roivant Sciences Ltd.
    (Name of Issuer)
    Common Shares
    (Title of Class of Securities)
    G76279 101
    (CUSIP Number)
    12/31/2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     1

    NAME OF REPORTING PERSON

    Vivek Ramaswamy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP       (a) ☐    (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S.

    NUMBER OF
    SHARES BENEFICIALLY OWNED
    BY EACH REPORTING PERSON
    WITH
    5

    SOLE VOTING POWER

    81,454,521 (1)

    6

    SHARED VOTING POWER

    -

    7

    SOLE DISPOSITIVE POWER

    81,454,521 (1)

    8

    SHARED DISPOSITIVE POWER

    -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    81,454,521 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.75%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

    (1) Consists of (i) 51,929,426 shares of restricted stock covering common shares that are fully vested (“RSAs”) and (ii) 29,525,095 common shares underlying stock options to purchase common shares (“Options”).

    (2) Percentage ownership is based on (i) 805,846,006 common shares issued and outstanding as of February 9, 2024 as disclosed by the Issuer in its Form 10-Q for the quarterly period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 13, 2024 and (ii) 25,525,095 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

     

     

     

     

    ITEM 1.(a) Name of Issuer:

    Roivant Sciences Ltd.

    (b)Address of Issuer’s Principal Executive Offices:

    7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom.

    ITEM 2.(a) Name of Person Filing:

    This Amendment to Schedule 13G (the “Amendment”) is being filed by Vivek Ramaswamy (the “Reporting Person”).

    (b)Address of Principal Business Office, or if None, Residence:

    PO BOX 20860
    COLUMBUS, OH 43220.

    (c)Citizenship or Place of Organization:

    See row 4 of the cover page to this Amendment.

    (d)Title of Class of Securities:

    Common Shares, $0.0000000341740141 per share.

    (e)CUSIP Number: G76279 101
    ITEM 3.IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

    Not Applicable.

    ITEM 4.OWNERSHIP.

    All calculations of percentage ownership herein are based on an aggregate of 835,371,101 common shares issued and outstanding as of February 9, 2024, based on (i) 805,846,006 common shares issued and outstanding as of February 9, 2024 as disclosed by the Issuer in its Form 10-Q for the quarterly period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 13, 2024 and (ii) 29,525,095 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

    The information set forth in Item 2 above is incorporated by reference for the Reporting Person.

    (a)Amount beneficially owned:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

    (b)Percent of class:

     

    9.75%

     

     

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

     

    (ii)Shared power to vote or to direct the vote:

     

    N/A

    (iii)Sole power to dispose or to direct the disposition of:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

    (iv)Shared power to dispose or to direct the disposition of:

     

    N/A

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    Not Applicable.

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Not Applicable.

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not Applicable.

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not Applicable.

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not Applicable.

    ITEM 10.CERTIFICATIONS.

    Not Applicable.

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

     

    By:  /s/ Vivek Ramaswamy      

    Name: Vivek Ramaswamy

     

     

    Get the next $ROIV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    10/27/2022$7.00Overweight
    JP Morgan
    5/23/2022$6.00Outperform
    SVB Leerink
    4/29/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ROIV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 6:53:25 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 5:29:42 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 4:35:35 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/14/24 4:31:06 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 4:58:58 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Roivant Sciences Ltd.

      SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 10:34:18 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CFO Pulik Richard covered exercise/tax liability with 3,487 shares, decreasing direct ownership by 0.86% to 402,212 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:39 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & COO Venker Eric covered exercise/tax liability with 39,148 shares, exercised 100,000 shares at a strike of $3.85 and sold $1,095,000 worth of shares (100,000 units at $10.95), decreasing direct ownership by 4% to 1,077,197 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:37 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Gline Matthew covered exercise/tax liability with 10,945 shares, decreasing direct ownership by 0.06% to 17,283,766 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:36 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Financials

    Live finance-specific insights

    See more
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Roivant Sciences with a new price target

      Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

      2/15/24 6:44:53 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Roivant Sciences with a new price target

      Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

      1/5/24 8:43:06 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Roivant Sciences with a new price target

      Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00

      12/12/23 8:08:23 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

      NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

      3/26/24 6:22:00 PM ET
      $PGTI
      $ROIV
      $RUN
      $SPGI
      Building Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

      BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

      11/10/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

        BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

      10/13/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care